VitreoRetinal Surgery PA, based in Minnesota, has joined Retina Consultants of America (RCA). This is the sixth retina specialty practice to join RCA as it continues to expand the company’s footprint across the United States, including California Retina Consultants, Retina Consultants of Houston, Retina Group of Florida, Long Island Vitreoretinal Consultants, and Retinal Consultants Serving Northern California.
VitreoRetinal Surgery PA is comprised of 13 retina specialists, and two retina fellows-in-training, across seven offices serving Minnesota, North Dakota, South Dakota, Iowa, and Wisconsin. These physicians have collectively authored or co-authored more than 200 scientific articles in their subspecialty and have been investigators in many randomized clinical trials studying new treatments for the retina, macula and vitreous.
“The physicians of VitreoRetinal Surgery are honored to partner with RCA’s other premier retina practices. The physicians in these practices are not only our long-term professional colleagues but also our friends,” David F. Williams, MD, VitreoRetinal Surgery, PA and past President of the American Society of Retina Specialists, said in a news release. “Together, and with the resources that RCA will provide, we intend to build the best retina organization in the world. We will serve the nation, and the world, by expanding the availability of our high-quality retina care, and by accelerating the pace of retinal clinical trials and research.”
Formed by Webster Equity Partners and headquartered in Southlake, Texas, RCA is partnering with leading retina specialists who seek a strategic partner with the capital resources and expertise to invest in their practice infrastructure and position them for continued growth in their markets. RCA is unique in that this is the first horizontal alliance in the eyecare field focused solely on retinal care.
“Our focus on high quality patient care and superior research through horizontal alliances continues to resonate with the premier retina groups in the nation,” said Robert Grabow, CEO of RCA. “We are pleased to have Dr. Williams and the team at VitreoRetinal Surgery, PA join RCA. Their commitment to research and advancing the field of retinal care makes them a perfect addition to our alliance.”
RCA is governed by a Medical Leadership Board that is co-chaired by Joel Pearlman, MD, PhD, and David M. Brown, MD. Drs. Pearlman and Brown are both leaders in clinical trials that led to the development of anti-VEGF injections for the treatment of macular degeneration, diabetic retinopathy and retinal vein occlusion.